Antiretroviral therapy coverage for PMTCT in Liberia

Liberia: Antiretroviral therapy coverage for PMTCT was 88.0% in 2024. ◆ Volatile

Latest (2024)
88.0%
Change on year
up 12.8%
World rank
31st
of 84 countries
All-time high
88.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Liberia, 2000–2024

0204060802000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 0 % of pregnant women living with HIV2003: 0 % of pregnant women living with HIV2004: 0 % of pregnant women living with HIV2005: 0 % of pregnant women living with HIV2006: 0 % of pregnant women living with HIV2007: 1 % of pregnant women living with HIV2008: 11 % of pregnant women living with HIV2009: 11 % of pregnant women living with HIV2010: 17 % of pregnant women living with HIV2011: 25 % of pregnant women living with HIV2012: 27 % of pregnant women living with HIV2013: 21 % of pregnant women living with HIV2014: 22 % of pregnant women living with HIV2015: 43 % of pregnant women living with HIV2016: 52 % of pregnant women living with HIV2017: 59 % of pregnant women living with HIV2018: 70 % of pregnant women living with HIV2019: 72 % of pregnant women living with HIV2020: 54 % of pregnant women living with HIV2021: 75 % of pregnant women living with HIV2022: 69 % of pregnant women living with HIV2023: 78 % of pregnant women living with HIV2024: 88 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

The most recent figure for antiretroviral therapy coverage for pmtct in Liberia is 88.0%, measured in 2024. That is the highest value across all 25 years on record.

The figure is up 12.8% on the previous year and up 300.0% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Liberia peaked at 88.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Liberia 31st out of 84 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Liberia, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Liberia, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 0.0%
2007 1.0%
2008 11.0% +1000.0%
2009 11.0% +0.0%
2010 17.0% +54.5%
2011 25.0% +47.1%
2012 27.0% +8.0%
2013 21.0% -22.2%
2014 22.0% +4.8%
2015 43.0% +95.5%
2016 52.0% +20.9%
2017 59.0% +13.5%
2018 70.0% +18.6%
2019 72.0% +2.9%
2020 54.0% -25.0%
2021 75.0% +38.9%
2022 69.0% -8.0%
2023 78.0% +13.0%
2024 88.0% +12.8%

Liberia compared with similar countries

  • Liberia's 88.0% is above the median for low income countries, which is 73.0%, 1.2× the median. (22 countries reporting)
  • Liberia's 88.0% is above the median for Sub-Saharan Africa, which is 82.0%, 1.1× the median. (41 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Liberia changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2008 +1000.0% 1.0% 11.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.3% 0.0% 11.0% 10
2010s 40.8% 17.0% 72.0% 10
2020s 72.8% 54.0% 88.0% 5

Countries ranked near Liberia

  1. 30 Cuba 89.0% compare
  2. 31 Cote d'Ivoire 88.0% compare
  3. 33 Togo 87.0% compare
  4. 34 Panama 86.0% compare

See the full ranking of 99 places →

More health data for Liberia

All data for Liberia →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Liberia?
Antiretroviral therapy coverage for pmtct in Liberia was 88.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Liberia?
The highest recorded value was 88.0% in 2024.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Liberia?
The lowest recorded value was 0.0% in 2000.
How does Liberia rank for antiretroviral therapy coverage for pmtct?
Liberia ranks 31st out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Liberia?
Over the last ten years it is up 300.0%. The long-run trend across the full record is volatile.
Where does this Liberia data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Liberia. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 18 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/liberia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/liberia/">Antiretroviral therapy coverage for PMTCT in Liberia</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).